BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

European Hematology Association Release: Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial


6/15/2012 10:18:56 AM

AMSTERDAM, June 15, 2012 /PRNewswire/ --

"Hodgkin lymphoma has become one of the most curable malignancies in adults," was stated by Dr Andreas Engert, Professor of Hematology at the University Hospital of Cologne in Germany. Results of the German Hodgkin Study Group (GHSG) HD 15 trial are presented at the 17th Congress of the European Hematology Association in Amsterdam.

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear. We thus conducted a prospectively randomized clinical trial comparing the standard of care (8 x BEACOPPescalated) with two reduced-intensity chemotherapy variants. Chemotherapy was followed by positron emission tomography (PET) guided radiotherapy. In total, 2182 patients with newly diagnosed advanced stage Hodgkin lymphoma were randomized. Treatment with 6 cycles of BEACOPPescalated was not only better tolerated than 8 cycles but resulted in improved tumor control (89.3% versus 84.4%) and overall survival (94.5% versus 91.9%). This was in part due to a lower mortality with 6 cycles as compared to 8 in terms of treatment related events (0.8% versus 2.1%) and secondary malignancies (0.7% versus 1.8%). In addition, the PET-guided radiotherapy resulted in a substantially reduced number of patients radiated in the present HD15 trial (11%). The outcome in HD15 was comparable to the prior HD9 study in which 70% had received additional radiotherapy. Thus, we suggested that 6 cycles of BEACOPPescalated is the treatment of choice for advanced stage Hodgkin lymphoma; PET performed after chemotherapy can guide the need of additional radiotherapy in this setting.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.

SOURCE European Hematology Association



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->